Skip to content

Released Nov 12, 2025, before the open

10-Q filed Nov 12, 2025, 43 days after period end · 0001576885-25-000104

Q3 2025 · 10-Q
Revenue—
Net Income-$26.45MN/M vs Q3 2024N/M vs Q2 2025
EPS Diluted-$0.44N/M vs Q3 2024N/M vs Q2 2025
Operating Income-$26,513,000N/M
Operating Cash Flowderived-$30,489,000N/M
Free Cash Flowderived-$30,489,000N/M

What the release said

The release

Same quarter

MetricQ3 2025Q3 2024Q3 2023Q3 2022
Net Income-$26.45M-$29.77M-$12.96M-$10.71M
EPS Diluted-$0.44-$0.50-$0.24-$0.26

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Acumen Pharmaceuticals, Inc. · CIK 1576885 · Engraved from SEC EDGAR